Generated by AI
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company’s lead program is obexelimab, a bifunctional monoclonal antibody being studied across multiple immune-mediated conditions, including IgG4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Zenas BioPharma also advances a broader pipeline of antibody-based and targeted therapies aimed at modulating immune pathways involved in chronic autoimmune disorders. Based in Waltham, Massachusetts, the company operates as a research-driven drug developer with current activities centered on clinical development, regulatory progress, and building a portfolio of therapies for patients with significant unmet medical needs.
Website852 Winter Street
Waltham, MA, 02451
United States
The latest articles about ZBIO.
- New patient and physician surveys reveal differing perspectives on disease burden, treatment goals, and long-term management - WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced The Distance Between platform and new findings from Zenas-sponsored patient and healthcare professional (HC
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived repl
Summary of May 19's posts. Generated by AI.
Summary of Jan 22's posts. Generated by AI.
No summary yet.
Summary of Mar 27's posts. Generated by AI.
Investors talking about ZBIO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.